PAUL BRENNAN

Chief Executive Officer

Paul Brennan was appointed as the Company's Chief Executive Officer on October 20, 2009.  Since May 2009 Mr. Brennan has been a Principal at Pacific BioPartners, a consulting company focusing on supporting Biotech companies, including MIGENIX, with general management and business development expertise. From August 2008 to April 2009 Mr Brennan was the CEO and a Board Member of Altair Therapeutics an emerging biopharmaceutical company based in San Diego and focused on developing inhaled therapeutics for respiratory diseases. In January 2007, Mr Brennan joined Aspreva Pharmaceuticals as Senior Vice President, Business Development, and was involved in the sale of the company to the Galenica Corporation for $920 million. Between 2002 and 2007 Mr Brennan worked for AnorMED, and held various positions in Business Development, Marketing and General Management. Mr Brennan was a Board Member and was Acting-President of AnorMED when it was sold to the Genzyme Corporation for $590 million. Prior to joining AnorMED Mr Brennan worked for AstraZeneca in a number of management positions in Business Development and Regulatory Affairs based in Canada, Sweden and the UK. Mr Brennan has a M.Sc and B. Sc from Queen's University in Kingston.

BRUCE SCHMIDT

President and Chief Financial Officer (Interim)

Bruce Schmidt was appointed as the Company's President and Chief Executive Officer (interim) in August 2008 and provides those services through his management company, RJS Management Ltd. Mr. Schmidt ceased to be the Company’s Chief Executive Officer effective October 20, 2009 with the appointment of Mr. Brennan. From 1993 to 2000, Mr. Schmidt was a founder and Chief Executive Officer of a University of British Columbia spin-off biotechnology company focused on novel compounds for the treatment of various cancers and neurological disorders. In 2000, Mr. Schmidt helped found Genome British Columbia, a life-sciences research institute with the objective of building world class genomics capabilities in Canada. Mr. Schmidt has also served as a director for a number of high-tech and biotech companies in Canada. Mr. Schmidt is currently a director of GreenAngel Energy Corp. and En2Go International Ltd.  Mr. Schmidt is a past-director of the Canadian Healthcare Licensing Association, past-Chair of the B.C. Nanotechnology Alliance and past-Chair of Life Sciences British Columbia (formerly BCBiotech).